Related Experiment Video
Updated: Mar 25, 2026
A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
Published on: March 4, 2017
Experimental Models for Evaluation of Nanoparticles in Cancer Therapy
Prashant Kesharwani1, Raksha Ghanghoria2, Narendra K Jain2
1Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI (48201). United States.
Abstract:
Nanoparticles (NPs), the submicron-sized colloidal particles, have recently generated enormous interest among biomedical scientists, particularly in cancer therapy. A number of models are being used for exploring NPs safety and efficacy. Recently, cancer cell lines have explored as prominent experimental models for evaluating pharmacokinetic parameters, cell viability, cytotoxicity and drug efficacy in tumor cells. This review aims at thorough compilation of various cancer cell lines and in vivo models for evaluation of efficacy of NPs on one platform. This will provide a basis to explore and improvise pre-clinical models as a prelude to successful cancer research.
Insights
This review compiles cancer cell lines and in vivo models for evaluating nanoparticle (NP) efficacy in cancer therapy. It aims to improve preclinical models for successful NP-based cancer research.
Area of Science:
- Biomedical Science
- Nanotechnology
- Cancer Research
Background:
- Nanoparticles (NPs) show promise in cancer therapy.
- Evaluating NP safety and efficacy requires robust experimental models.
- Cancer cell lines are increasingly used for preclinical drug evaluation.
Purpose of the Study:
- To compile various cancer cell lines and in vivo models for NP efficacy evaluation.
- To provide a unified platform for assessing nanoparticle performance in cancer research.
- To guide the improvement of preclinical models for nanoparticle-based cancer therapies.
Main Methods:
- Literature review of preclinical models for nanoparticle evaluation.
- Compilation of studies utilizing cancer cell lines for pharmacokinetic and cytotoxicity assessments.
- Analysis of in vivo models employed in nanoparticle efficacy studies for cancer.
Main Results:
- Identified diverse cancer cell lines and in vivo models used in nanoparticle research.
- Highlighted the role of cell lines in evaluating NP pharmacokinetics, viability, and cytotoxicity.
- Demonstrated the necessity of comprehensive preclinical models for nanoparticle drug efficacy.
Conclusions:
- A consolidated understanding of preclinical models is crucial for advancing nanoparticle cancer therapy.
- Standardizing and improving these models will enhance the translation of NP research to clinical success.
- This review serves as a foundation for optimizing nanoparticle preclinical evaluation in oncology.
